Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. Oct 15, 2016
Video: An Overview of Our 16-page Stock Research Reports
President of Equity Research, Brian Nelson, walks through how financial advisors and individual investors can get the most out of Valuentum's 16-page equity report. Oct 13, 2016
Understanding the Chartered Financial Analyst (CFA) Designation
Let's examine why the Economist (magazine) calls the CFA the gold standard in the investment industry. Jun 12, 2016
Dividend Increases/Decreases for the Week Ending June 10
Let's take a look at companies raising/lowering their dividends this week. Jun 9, 2016
Recent Coverage Additions: FDC, ALLE, EW, UNH, SIMO
We've added coverage of First Data (FDC), Allegion (ALLE), Edwards Lifesciences (EW), UnitedHealth Group (UNH), and Silicon Motion Technology (SIMO). Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Jun 16, 2015
Target-CVS Agreement: What It Really Means
Target and CVS recently signed a major partnership, but a Best Ideas Newsletter portfolio holding may benefit the most from the agreement. Let’s take a closer look at effects of the deal. Jun 7, 2015
Dividend Increases/Decreases for the Week Ending June 5
Let's take a look at companies raising/lowering their dividends this week. Jun 9, 2014
Dividend Increases for the Week Ending June 6
Let's take a look at dividend increases for the week ending June 6. Feb 28, 2014
Thank you…
We can’t begin to tell you how much we appreciate feedback. Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
